UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the quarterly period ended September 26, 2020
Or
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the transition period from
to
Commission file number: 0-27598
IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
|
|
77-0210467
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
1212 Terra Bella Avenue
Mountain View, California
|
|
94043-1824
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(650) 940-4700
Securities registered pursuant to Section 12(b) of the
Act:
Title of Class
|
|
Trading Symbol
|
|
Name of Exchange on Which Registered
|
Common Stock, par value $0.01 per share
|
|
IRIX
|
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past
90 days. Yes ☑
No ☐
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such
files). Yes ☑
No ☐
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
|
|
|
Non-accelerated filer
|
|
☑
|
|
Smaller reporting company
|
|
☑
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
|
|
|
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange
Act). Yes ☐
No ☑
The number of shares of common stock, $0.01 par value, issued and
outstanding as of October 22, 2020 was 13,897,563.
TABLE
OF CONTENTS
Items
|
|
|
Page
|
|
|
|
|
PART I. FINANCIAL
INFORMATION
|
5
|
|
|
|
|
Item 1.
|
|
Condensed Consolidated Financial Statements
(Unaudited)
|
5
|
|
|
|
|
|
|
Unaudited Condensed Consolidated Balance Sheets as of September 26,
2020 and December 28, 2019
|
5
|
|
|
|
|
|
|
Unaudited Condensed Consolidated Statements of Operations
for the three and nine months ended
September 26, 2020 and September 28, 2019
|
6
|
|
|
|
|
|
|
Unaudited Condensed Consolidated Statements of Comprehensive Loss
for the three and nine months ended
September 26, 2020 and September 28, 2019
|
7
|
|
|
|
|
|
|
Unaudited Condensed Consolidated Statements of Stockholder's Equity
for the three and nine months ended
September 26, 2020 and September 28, 2019
|
8
|
|
|
|
|
|
|
Unaudited Condensed Consolidated Statements of Cash Flows for the
nine months ended September 26, 2020 and September 28,
2019
|
9
|
|
|
|
|
|
|
Notes to Unaudited Condensed Consolidated Financial
Statements
|
10
|
|
|
|
|
Item 2.
|
|
Management’s Discussion and Analysis of Financial Condition and
Results of Operations
|
21
|
|
|
|
|
Item 3.
|
|
Quantitative and Qualitative Disclosures about Market
Risk
|
25
|
|
|
|
|
Item 4.
|
|
Controls and Procedures
|
25
|
|
|
|
|
PART II. OTHER INFORMATION
|
26
|
|
|
|
|
Item 1.
|
|
Legal Proceedings
|
26
|
|
|
|
|
Item 1A.
|
|
Risk Factors
|
26
|
|
|
|
|
Item 2.
|
|
Unregistered Sales of Equity Securities and Use of
Proceeds
|
43
|
|
|
|
|
Item 3.
|
|
Defaults Upon Senior Securities
|
43
|
|
|
|
|
Item 4.
|
|
Mine Safety Disclosures
|
43
|
|
|
|
|
Item 5.
|
|
Other Information
|
43
|
|
|
|
|
Item 6.
|
|
Exhibits
|
44
|
|
|
|
|
Signatures
|
45
|
2
NOTE
REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, which statements involve substantial risks and
uncertainties. Forward-looking statements generally relate to
future events or our future financial or operating performance. In
some cases, you can identify forward-looking statements because
they contain words such as “may,”
“will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these words or other
similar terms or expressions that concern our expectations,
strategy, plans, or intentions. Forward-looking statements
contained in this Quarterly Report on Form 10-Q include, but are
not limited to, statements about:
|
•
|
our future financial
performance, including our expectations regarding our revenue, cost
of revenue, gross profit or gross margin, operating expenses
(including changes in sales and marketing, research and development
and general and administrative expenses), and our ability to
achieve and maintain future profitability;
|
|
•
|
the impact of the
COVID-19 pandemic and related responses of business and governments
to the pandemic on our operations and personnel, and on commercial
activity and demand of our products, business operations and
results of operations;
|
|
•
|
our ability to raise
additional capital;
|
|
•
|
customer acceptance and
purchase of our existing products and new products;
|
|
•
|
our ability to maintain
and expand our customer base;
|
|
•
|
competition from other
products;
|
|
•
|
the impact of foreign
currency exchange rate and interest rate fluctuations on our
results and sales;
|
|
•
|
the pace of change and
innovation in the markets in which we participate and the
competitive nature of those markets;
|
|
•
|
our business strategy
and our plan to build our business;
|
|
•
|
our ability to
effectively manage our growth;
|
|
•
|
our costs of
manufacturing and reliance on third party manufacturers;
|
|
•
|
our ability to forecast
and meet product demand;
|
|
•
|
our ability to discover
defects in our products and systems;
|
|
•
|
our international
expansion and sales strategy;
|
|
•
|
our operating results
and cash flows;
|
|
•
|
our beliefs and
objectives for future operations;
|
|
•
|
our relationships with
third parties;
|
|
•
|
our ability to maintain,
protect, and enhance our intellectual property rights;
|
|
•
|
our ability to maintain,
protect, and enhance our information technology systems and
data;
|
|
•
|
our ability to maintain
our facilities in good working order;
|
|
•
|
our ability to recover
the carrying value of goodwill;
|
|
•
|
the impact of expensing
stock options and other equity awards;
|
|
•
|
our ability to
successfully defend litigation brought against us;
|
|
•
|
our ability to indemnify
our directors and officers;
|
|
•
|
our ability to repay
indebtedness and have indebtedness forgiven;
|
|
•
|
our ability to
successfully expand in our existing markets and into new
markets;
|
|
•
|
sufficiency of cash to
meet cash needs for at least the next 12 months;
|
|
•
|
our ability to comply
with laws, policies, and regulations that currently apply or become
applicable to our business both in the United States and
internationally;
|
|
•
|
our ability to attract
and retain qualified employees, key personnel, and source
suppliers;
|
|
•
|
the future trading
prices of our common stock; and
|
|
•
|
our ability to pay
dividends in the future.
|
3
In addition, statements that “we
believe”
and similar statements reflect our beliefs and opinions on the
relevant subject. These statements are based upon information
available
to us as of the date of this Quarterly Report on Form 10-Q, and
while we believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our
statements should not be read to indicate that we have
conducted
an exhaustive inquiry into, or review of, all potentially available
relevant information. These statements are inherently uncertain and
investors are cautioned not to unduly rely upon these
statements.
You
should not rely upon forward-looking statements as predictions of
future events. We have based the forward-looking statements
contained in this Quarterly Report on Form 10-Q primarily on our
current expectations and projections about future events and trends
that we believe may affect our business, financial condition,
results of operations, and prospects. The outcome of the events
described in these forward-looking statements is subject to risks,
uncertainties, and other factors described in the section titled
“Risk Factors” and elsewhere in this Quarterly Report on
Form 10-Q. Moreover, we operate in a very competitive and rapidly
changing environment. New risks and uncertainties emerge from time
to time, and it is not possible for us to predict all risks and
uncertainties that could have an impact on the forward-looking
statements contained in this Quarterly Report on Form 10-Q. We
cannot assure you that the results, events, and circumstances
reflected in the forward-looking statements will be achieved or
occur, and actual results, events, or circumstances could differ
materially from those described in the forward-looking
statements.
The forward-looking statements made in this Quarterly Report on
Form 10-Q relate only to events as of the date on which such
statements are made. We undertake no obligation to update any
forward-looking statements made in this Quarterly Report on Form
10-Q to reflect events or circumstances after the date of this
Quarterly Report on Form 10-Q or to conform such statements to
actual results or revised expectations, except as required by law.
We may not actually achieve the plans, intentions, or expectations
disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Our
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures, or
investments we may make.
As used in this Quarterly Report on Form 10-Q, the terms “Company,”
“IRIDEX,” “we,” “us” and “our” refer to IRIDEX Corporation, and its
consolidated subsidiaries.
4
PART I.
FINANCIAL
INFORMATION
Item 1.
Condensed Consolidated Financial Statements (Unaudited)
IRIDEX Corporation
CONDENSED
CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands except share and per share data)
|
|
September 26, 2020
|
|
|
December 28, 2019 (1)
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
11,932
|
|
|
$
|
12,653
|
|
Accounts receivable, net of allowance for doubtful accounts of
$278 as of September 26, 2020 and $187 as of December 28, 2019
|
|
|
6,083
|
|
|
|
9,323
|
|
Inventories
|
|
|
7,004
|
|
|
|
8,174
|
|
Prepaid expenses and other current assets
|
|
|
542
|
|
|
|
401
|
|
Total current assets
|
|
|
25,561
|
|
|
|
30,551
|
|
Property and equipment, net
|
|
|
451
|
|
|
|
730
|
|
Intangible assets, net
|
|
|
72
|
|
|
|
84
|
|
Goodwill
|
|
|
533
|
|
|
|
533
|
|
Operating lease right-of-use assets, net
|
|
|
1,693
|
|
|
|
2,764
|
|
Other long-term assets
|
|
|
149
|
|
|
|
151
|
|
Total assets
|
|
$
|
28,459
|
|
|
$
|
34,813
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,475
|
|
|
$
|
2,592
|
|
Accrued compensation
|
|
|
1,889
|
|
|
|
2,398
|
|
Accrued expenses
|
|
|
1,682
|
|
|
|
1,544
|
|
Current portion of PPP loan
|
|
|
1,526
|
|
|
|
—
|
|
Accrued warranty
|
|
|
182
|
|
|
|
380
|
|
Deferred revenue
|
|
|
1,072
|
|
|
|
1,450
|
|
Operating lease liabilities
|
|
|
1,387
|
|
|
|
1,414
|
|
Total current liabilities
|
|
|
9,213
|
|
|
|
9,778
|
|
Long-term liabilities:
|
|
|
|
|
|
|
|
|
PPP loan
|
|
|
971
|
|
|
|
—
|
|
Accrued warranty
|
|
|
102
|
|
|
|
156
|
|
Deferred revenue
|
|
|
286
|
|
|
|
360
|
|
Operating lease liabilities
|
|
|
616
|
|
|
|
1,795
|
|
Other long-term liabilities
|
|
|
19
|
|
|
|
19
|
|
Total liabilities
|
|
|
11,207
|
|
|
|
12,108
|
|
Commitments and contingencies (Note 7)
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, 2,000,000 shares authorized, no
shares
issued and outstanding
|
|
|
—
|
|
|
|
—
|
|
Common stock, $0.01 par value:
|
|
|
|
|
|
|
|
|
Authorized: 30,000,000 shares;
|
|
|
|
|
|
|
|
|
Issued and outstanding 13,897,353 and 13,785,233 shares
as of September 26, 2020 and December 28, 2019, respectively
|
|
|
148
|
|
|
|
147
|
|
Additional paid-in capital
|
|
|
73,837
|
|
|
|
73,093
|
|
Accumulated other comprehensive income
|
|
|
32
|
|
|
|
80
|
|
Accumulated deficit
|
|
|
(56,765
|
)
|
|
|
(50,615
|
)
|
Total stockholders’ equity
|
|
|
17,252
|
|
|
|
22,705
|
|
Total liabilities and stockholders’ equity
|
|
$
|
28,459
|
|
|
$
|
34,813
|
|
(1)
|
Derived from the audited consolidated financial statements included
in the Annual Report on Form 10-K filed with the SEC for the year
ended December 28, 2019.
|
The accompanying notes are an integral part of these condensed
consolidated financial statements.
5
IRIDEX
Corporation
Condensed
Consolidated Statements of Operations
(Unaudited, in thousands except per share data)
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 26, 2020
|
|
|
September 28, 2019
|
|
|
September 26, 2020
|
|
|
September 28, 2019
|
|
Total revenues
|
|
$
|
8,803
|
|
|
$
|
10,664
|
|
|
$
|
24,043
|
|
|
$
|
31,685
|
|
Cost of revenues
|
|
|
5,149
|
|
|
|
6,381
|
|
|
|
14,067
|
|
|
|
18,596
|
|
Gross profit
|
|
|
3,654
|
|
|
|
4,283
|
|
|
|
9,976
|
|
|
|
13,089
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
869
|
|
|
|
1,007
|
|
|
|
2,395
|
|
|
|
2,894
|
|
Sales and marketing
|
|
|
2,959
|
|
|
|
3,508
|
|
|
|
8,804
|
|
|
|
11,061
|
|
General and administrative
|
|
|
1,672
|
|
|
|
1,621
|
|
|
|
5,060
|
|
|
|
6,491
|
|
Total operating expenses
|
|
|
5,500
|
|
|
|
6,136
|
|
|
|
16,259
|
|
|
|
20,446
|
|
Loss from operations
|
|
|
(1,846
|
)
|
|
|
(1,853
|
)
|
|
|
(6,283
|
)
|
|
|
(7,357
|
)
|
Other income, net
|
|
|
135
|
|
|
|
75
|
|
|
|
153
|
|
|
|
127
|
|
Loss from operations before provision for income taxes
|
|
|
(1,711
|
)
|
|
|
(1,778
|
)
|
|
|
(6,130
|
)
|
|
|
(7,230
|
)
|
Provision for income taxes
|
|
|
8
|
|
|
|
7
|
|
|
|
20
|
|
|
|
22
|
|
Net loss
|
|
$
|
(1,719
|
)
|
|
$
|
(1,785
|
)
|
|
$
|
(6,150
|
)
|
|
$
|
(7,252
|
)
|
Net loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.12
|
)
|
|
$
|
(0.13
|
)
|
|
$
|
(0.44
|
)
|
|
$
|
(0.53
|
)
|
Diluted
|
|
$
|
(0.12
|
)
|
|
$
|
(0.13
|
)
|
|
$
|
(0.44
|
)
|
|
$
|
(0.53
|
)
|
Weighted average shares used in computing net loss
per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
13,893
|
|
|
|
13,768
|
|
|
|
13,824
|
|
|
|
13,682
|
|
Diluted
|
|
|
13,893
|
|
|
|
13,768
|
|
|
|
13,824
|
|
|
|
13,682
|
|
The accompanying notes are an integral part of these condensed
consolidated financial statements.
6
IRIDEX Corporation
Condensed
Consolidated Statements of Comprehensive Loss
(Unaudited, in thousands)
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 26, 2020
|
|
|
September 28, 2019
|
|
|
September 26, 2020
|
|
|
September 28, 2019
|
|
Net loss
|
|
$
|
(1,719
|
)
|
|
$
|
(1,785
|
)
|
|
$
|
(6,150
|
)
|
|
$
|
(7,252
|
)
|
Foreign currency translation adjustments
|
|
|
(41
|
)
|
|
|
36
|
|
|
|
(48
|
)
|
|
|
32
|
|
Comprehensive loss
|
|
$
|
(1,760
|
)
|
|
$
|
(1,749
|
)
|
|
$
|
(6,198
|
)
|
|
$
|
(7,220
|
)
|
The accompanying notes are an integral part of these condensed
consolidated financial statements.
7
IRIDEX Corporation
Condensed
Consolidated Statements of Stockholders' Equity
(Unaudited, in thousands, except share data)
For the three months ended September 26, 2020
|
|
Common Stock
|
|
|
Additional
Paid-in
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Income
|
|
|
Deficit
|
|
|
Total
|
|
Balances, June 27, 2020
|
|
|
13,856,969
|
|
|
$
|
148
|
|
|
$
|
73,619
|
|
|
$
|
73
|
|
|
$
|
(55,046
|
)
|
|
$
|
18,794
|
|
Employee stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
243
|
|
|
|
|
|
|
|
|
|
|
|
243
|
|
Release of restricted stock, net of taxes paid
|
|
|
40,384
|
|
|
|
-
|
|
|
|
(25
|
)
|
|
|
|
|
|
|
|
|
|
|
(25
|
)
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(41
|
)
|
|
|
|
|
|
|
(41
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,719
|
)
|
|
|
(1,719
|
)
|
Balances, September 26, 2020
|
|
|
13,897,353
|
|
|
$
|
148
|
|
|
$
|
73,837
|
|
|
$
|
32
|
|
|
$
|
(56,765
|
)
|
|
$
|
17,252
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the nine months ended September 26, 2020
|
|
Common Stock
|
|
|
Additional
Paid-in
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Income
|
|
|
Deficit
|
|
|
Total
|
|
Balances, December 28, 2019
|
|
|
13,785,233
|
|
|
$
|
147
|
|
|
$
|
73,093
|
|
|
$
|
80
|
|
|
$
|
(50,615
|
)
|
|
$
|
22,705
|
|
Employee stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
774
|
|
|
|
|
|
|
|
|
|
|
|
774
|
|
Release of restricted stock, net of taxes paid
|
|
|
112,120
|
|
|
1
|
|
|
|
(30
|
)
|
|
|
|
|
|
|
|
|
|
|
(29
|
)
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(48
|
)
|
|
|
|
|
|
|
(48
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,150
|
)
|
|
|
(6,150
|
)
|
Balances, September 26, 2020
|
|
|
13,897,353
|
|
|
$
|
148
|
|
|
$
|
73,837
|
|
|
$
|
32
|
|
|
$
|
(56,765
|
)
|
|
$
|
17,252
|
|
For the three months ended September 28, 2019
|
|
Common Stock
|
|
|
Additional
Paid-in
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Income
|
|
|
Deficit
|
|
|
Total
|
|
Balances, June 29, 2019
|
|
|
13,746,959
|
|
|
$
|
147
|
|
|
$
|
72,685
|
|
|
$
|
66
|
|
|
$
|
(47,269
|
)
|
|
$
|
25,629
|
|
Employee stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
158
|
|
|
|
|
|
|
|
|
|
|
|
158
|
|
Release of restricted stock, net of taxes paid
|
|
|
31,913
|
|
|
0
|
|
|
|
(50
|
)
|
|
|
|
|
|
|
|
|
|
|
(50
|
)
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36
|
|
|
|
|
|
|
|
36
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,785
|
)
|
|
|
(1,785
|
)
|
Balances, September 28, 2019
|
|
|
13,778,872
|
|
|
$
|
147
|
|
|
$
|
72,793
|
|
|
$
|
102
|
|
|
$
|
(49,054
|
)
|
|
$
|
23,988
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the nine months ended September 28, 2019
|
|
Common Stock
|
|
|
Additional
Paid-in
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Income
|
|
|
Deficit
|
|
|
Total
|
|
Balances, December 29, 2018
|
|
|
13,602,052
|
|
|
$
|
145
|
|
|
$
|
71,548
|
|
|
$
|
70
|
|
|
$
|
(41,802
|
)
|
|
$
|
29,961
|
|
Issuance of common stock under stock
option plan
|
|
|
210
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
—
|
|
Employee stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
1,398
|
|
|
|
|
|
|
|
|
|
|
|
1,398
|
|
Release of restricted stock, net of taxes paid
|
|
|
176,610
|
|
|
2
|
|
|
|
(153
|
)
|
|
|
|
|
|
|
|
|
|
|
(151
|
)
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
|
32
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,252
|
)
|
|
|
(7,252
|
)
|
Balances, September 28, 2019
|
|
|
13,778,872
|
|
|
$
|
147
|
|
|
$
|
72,793
|
|
|
$
|
102
|
|
|
$
|
(49,054
|
)
|
|
$
|
23,988
|
|
The accompanying notes are an integral part of these condensed
consolidated financial statements.
8
IRIDEX Corporation
Condensed
Consolidated Statements of Cash Flows
(Unaudited, in thousands)
|
|
Nine Months Ended
|
|
|
|
September 26, 2020
|
|
|
September 28, 2019
|
|
Operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(6,150
|
)
|
|
$
|
(7,252
|
)
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
399
|
|
|
|
534
|
|
Change in fair value of earn-out liability
|
|
|
—
|
|
|
|
47
|
|
Stock-based compensation
|
|
|
774
|
|
|
|
1,398
|
|
Provision for doubtful accounts
|
|
|
138
|
|
|
|
25
|
|
Loss on sale of property and equipment
|
|
|
13
|
|
|
|
—
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
3,110
|
|
|
|
265
|
|
Inventories
|
|
|
1,155
|
|
|
|
(188
|
)
|
Prepaid expenses and other current assets
|
|
|
(141
|
)
|
|
|
(43
|
)
|
Operating lease right-of-use assets
|
|
|
1,073
|
|
|
|
922
|
|
Other long-term assets
|
|
|
5
|
|
|
|
11
|
|
Accounts payable
|
|
|
(1,117
|
)
|
|
|
(86
|
)
|
Accrued compensation
|
|
|
(510
|
)
|
|
|
(1,015
|
)
|
Accrued expenses
|
|
|
135
|
|
|
|
(726
|
)
|
Accrued warranty
|
|
|
(252
|
)
|
|
|
(347
|
)
|
Deferred revenue
|
|
|
(452
|
)
|
|
|
(331
|
)
|
Operating lease liabilities
|
|
|
(1,209
|
)
|
|
|
(938
|
)
|
Net cash used in operating activities
|
|
|
(3,029
|
)
|
|
|
(7,724
|
)
|
Investing activities:
|
|
|
|
|
|
|
|
|
Acquisition of property and equipment
|
|
|
(87
|
)
|
|
|
(125
|
)
|
Payment on earn-out liability
|
|
|
—
|
|
|
|
(318
|
)
|
Proceeds from sale of property and equipment
|
|
|
3
|
|
|
|
—
|
|
Net cash used in investing activities
|
|
|
(84
|
)
|
|
|
(443
|
)
|
Financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from PPP loan
|
|
|
2,497
|
|
|
|
—
|
|
Taxes paid related to net share settlements of equity awards
|
|
|
(29
|
)
|
|
|
(151
|
)
|
Net cash provided by (used in) financing activities
|
|
|
2,468
|
|
|
|
(151
|
)
|
Effect of foreign exchange rate changes
|
|
|
(76
|
)
|
|
|
72
|
|
Net decrease in cash and cash equivalents
|
|
|
(721
|
)
|
|
|
(8,246
|
)
|
Cash and cash equivalents, beginning of period
|
|
|
12,653
|
|
|
|
21,194
|
|
Cash and cash equivalents, end of period
|
|
$
|
11,932
|
|
|
$
|
12,948
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|
|
|
|
|
Cash (received) paid during the period for income taxes
|
|
$
|
(25
|
)
|
|
$
|
19
|
|
Supplemental disclosure of non-cash activities:
|
|
|
|
|
|
|
|
|
Transfer of inventory to property and equipment
|
|
$
|
36
|
|
|
$
|
65
|
|
The accompanying notes are an integral part of these condensed
consolidated financial statements.
9
IRIDEX Corporation
Notes
to Unaudited Condensed Consolidated Financial Statements
1. Basis of Presentation
The accompanying unaudited condensed consolidated financial
statements of IRIDEX Corporation (“IRIDEX”, the “Company”, “we”,
“our”, or “us”) have been prepared in accordance with accounting
principles generally accepted in the United States (“U.S. GAAP”)
for interim financial information and pursuant to the instructions
to Form 10-Q and Article 10-01 of Regulation S-X.
Accordingly, they do not include all of the information and
footnotes required by U.S. GAAP for complete financial
statements. In the opinion of management, all adjustments,
consisting of normal recurring adjustments, considered necessary
for a fair presentation of the financial statements have been
included.
The accompanying unaudited condensed consolidated financial
statements should be read in conjunction with the audited
consolidated financial statements and notes thereto, together with
management’s discussion and analysis of the Company’s financial
condition and results of operations, contained in our Annual Report
on Form 10-K for the fiscal year ended December 28, 2019, which was
filed with the Securities and Exchange Commission (“SEC”) on March
13, 2020. The results of operations for the three and nine months
ended September 26, 2020 and September 28, 2019 are not necessarily
indicative of the results for the fiscal year ending January 2,
2021 or any future interim period. The three and nine months ended
September 26, 2020 and September 28, 2019, each had 13 weeks. For
purposes of reporting the financial results, the Company’s fiscal
years end on the Saturday closest to the end of December.
Periodically, the Company includes a 53rd week to a year in order
to end that year on the Saturday closest to the end of
December.
Liquidity.
We have historically funded our operations primarily through sales
of our products to customers, and through common stock and
borrowing arrangements. As of September 26, 2020, our principal
sources of liquidity consisted of cash and cash equivalents of
$11.9 million. We have incurred net losses over the last several
years, and as of September 26, 2020, have an accumulated deficit of
approximately $56.8 million. We expect to continue to incur
operating losses and negative cash flows from operations through
October 2, 2021.
We believe our existing cash and cash equivalents will be
sufficient to meet our anticipated cash needs over the next 12
months. Our future capital requirements will depend on many
factors, including our growth rate, the timing and extent of our
spending to support research and development activities, the timing
and cost of establishing additional sales and marketing
capabilities, the introduction of new and enhanced products and our
costs to implement new manufacturing technologies. In the event
that additional financing is required from outside sources, we may
not be able to raise it on terms acceptable to us or at all. Any
debt financing obtained by us in the future could also involve
restrictive covenants relating to our capital-raising activities
and other financial and operational matters, which may make it more
difficult for us to obtain additional capital and to pursue
business opportunities, including potential acquisitions.
Additionally, if we raise additional funds through further
issuances of equity, our existing stockholders could suffer
significant dilution in their percentage ownership of our company,
and any new equity securities we issue could have rights,
preferences and privileges senior to those of holders of our common
stock. If we are unable to obtain adequate financing or financing
on terms satisfactory to us, when we require it, our ability to
continue to grow or support our business and to respond to business
challenges could be significantly limited.
2. Summary of Significant Accounting Policies
The Company’s significant accounting policies are disclosed in our
Annual Report on Form 10-K for the year ended December 28, 2019,
which was filed with the SEC on March 13, 2020.
Financial Statement Presentation.
The unaudited condensed consolidated financial statements include
the accounts of the Company and our wholly owned subsidiaries. All
significant intercompany accounts and transactions have been
eliminated in consolidation.
Use of Estimates.
The preparation of consolidated financial statements in conformity
with U.S. GAAP requires us to make estimates and judgments that
affect the reported amounts of assets, liabilities, revenues, and
expenses and the related disclosure of contingent assets and
liabilities. We base our estimates on historical experience and on
various other assumptions that we believe to be reasonable under
the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may
differ from these estimates. In addition, any change in these
estimates or their related assumptions could have an adverse effect
on our operating results.
10
Revenue Recognition.
Our revenues arise from the sale of laser consoles, delivery
devices, consumables, service, and support activities. We also
derive revenue from royalties from third parties which are
typically based on licensees’ net sales of products that utilize
our technology. Our revenue is recognized in accordance with
Accounting Standards Codification (“ASC”) 606, “Revenue from
Contracts with Customers.”
The Company has the following revenue transaction types: (1)
Product Sale Only, (2) Laser Advantage Program (LAP), (3) Service
Contracts, (4) System Repairs (outside of warranty) and (5) Royalty
Revenue.
|
(1)
|
Product Sale Only: The Company’s
products consist of laser consoles, delivery devices and consumable
instrumentation, including laser probes. The Company’s products are
currently sold for use by ophthalmologists specializing in the
treatment of glaucoma and retinal diseases. Inside the United
States and Germany the products are sold directly to the end
users. In other countries outside of the United States
and Germany, the Company utilizes independent, third-party
distributors to market and sell the Company’s products. There
is no continuing obligation subsequent to the shipment to these
distributors.
|
The Company recognizes revenue from product sale at a point in
time. When a system or disposables are sold without any additional
deliverables, the Company recognizes revenue using the five-step
model: (1) identifying the contract with the customer, (2)
identifying the performance obligations in the contract, (3)
determining expected transaction price, (4) allocating the
transaction price to the distinct performance obligations in the
contract, and (5) recognizing revenue when (or as) the performance
obligations are satisfied.
|
(2)
|
LAP Program: The Company sometimes
enters into LAP contracts with customers. Under the LAP program,
the system is given away free of charge and title is transferred
after the customer purchases the minimum required number of boxes
of probes (classified as disposables). Customers with older
machines have the ability to trade in their old machines for the
most current laser equipment offered in the program (Cyclo G6
Laser) and receive a discount on the program’s minimum purchase
requirements. Under ASC 606, this non-cash consideration must be
included in the transaction price. However, the Company has
determined that there is no value associated with the old machines
and the trade in is essentially offered to encourage customers to
purchase more consumables under the program.
|
The Company recognizes revenue from product sales under the LAP
program at a point in time. The Company allocates the transaction
price of the distinct performance obligations in the contract by
determining stand-alone selling price using historical pricing net
of any variable consideration or discounts to specifically allocate
to a particular performance obligation.
|
(3)
|
Service Contracts: The
Company offers a standard two-year warranty on all system sales.
The Company also offers a service contract which is sold to
customers in incremental, one-year periods which begin subsequent
to the expiration of the standard two-year warranty. The customer
can opt to purchase the service contract at the time of the system
sale or after the initial system sale.
|
The Company recognizes revenue from service contracts ratably over
the service period. Revenue recognition for the sale of a service
contract is largely dependent on the timing of the sale as
follows:
|
a.
|
Service Contract Sale in Conjunction
with System Sale: If the customer opts to purchase a service
contract at the time of the system sale, the Company
allocates the transaction price of the distinct performance
obligations in the contract by determining stand-alone selling
price using historical pricing net of any variable consideration or
discounts to specifically allocate to a particular performance
obligation.
|
|
b.
|
Service Contract Sale Subsequent to
System Sale: If the customer opts to purchase a service contract
after the initial system sale, the Company determines the amount of
time that has elapsed since the initial system sale. If the service
contract is purchased within 60 days of the initial sale, the Company considers this
sale to be an additional element of the original sale and allocates
the transaction price of the distinct performance obligations in
the contract by determining stand-alone selling price using
historical pricing net of any variable consideration or discounts
to specifically allocate to a particular performance obligation. If
the service contract is purchased subsequent to sixty days after
the initial sale, the sale of the service contract is deemed a
separate contract and is deferred at the selling price and
recognized ratably over the extended warranty period as the
performance obligation is satisfied.
|
|
(4)
|
System Repairs (outside of warranty):
Customers will occasionally request repairs from the Company
subsequent to the expiration of the standard warranty and outside
of a service contract.
|
The Company recognizes revenue from system repairs (outside of
warranty) at a point in time. When the customer requests repairs
from the Company subsequent to the expiration of the standard
warranty and outside of a service contract, these repair contracts
are considered separate from the initial sale, and as such, revenue
is recognized as the repair services are rendered and the
performance obligation satisfied.
11
|
(5)
|
Royalty Revenue: The Company has royalty
agreements with two customers related to sale of the
Company’s
intellectual property. Under the terms of these agreements, the
customer is to remit a percentage of sales to the
Company.
|
Since these arrangements are for sales-based licenses of
intellectual property, for which the guidance in paragraph ASC
606-10-55-65 applies, the Company recognizes revenue only as the
subsequent sale occurs. However, the Company notes that such sales
being reported by the licensee with a quarter in arrear, such
revenue is recognized at the time it is reported and paid by the
licensee given that any estimated variable consideration would have
to be fully constrained due to the unpredictability of such
estimate and the unavoidable risk that it may lead to significant
revenue reversals.
The Company elected the practical expedient allowing it to not
recognize as a contract asset the commission paid to its salesforce
on the sale of its products as an incremental cost of obtaining a
contract with a customer but rather recognize such commission as
expense when incurred as the amortization period of the asset that
the Company would have otherwise recognized is one year or
less.
Leases.
We determine if an arrangement is a lease at inception. Operating
leases are included in Operating lease right-of-use (“ROU”) assets,
net and Operating lease liabilities in our condensed consolidated
balance sheets. As of September 26, 2020 and as of December 28,
2019, the Company was not a party to finance lease
arrangements.
ROU assets represent our right to use an underlying asset for the
lease term and lease liabilities represent our obligation to make
lease payments arising from the lease. Operating lease ROU assets
and liabilities are recognized at commencement date based on the
present value of lease payments over the lease term. As most of our
leases do not provide an implicit rate, we use our incremental
borrowing rate based on information available at commencement date
in determining the present value of lease payments. We use the
implicit rate when readily determinable. The operating lease ROU
asset also includes any lease payments made and excludes lease
incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will
exercise that option. Lease expense for lease payments is
recognized on a straight-line basis over the lease term.
Under the available practical expedient, we account for the lease
and non-lease components as a single lease component.
Concentration of Credit Risk.
Our cash and cash equivalents are deposited in demand and money
market accounts. Deposits held with banks may exceed the amount of
insurance provided on such deposits. Generally, these deposits may
be redeemed upon demand and therefore, bear minimal risk.
We market our products to distributors and end-users throughout the
world. Sales to international distributors are generally made on
open credit terms and letters of credit. Management performs
ongoing credit evaluations of our customers and maintains an
allowance for potential credit losses. Historically, we have not
experienced any significant losses related to individual customers
or a group of customers in any particular geographic area. For the
three and nine months ended September 26, 2020, no single customer
accounted for more than 10% of total revenues. For the three and
nine months ended September 28, 2019, no single customer accounted
for more than 10% of total revenues. As of September 26,
2020, no customer accounted for over 10% of our accounts
receivable. As of December 28, 2019, one customer accounted for
more than 10% of our accounts receivable, representing 11%.
Taxes Collected from Customers and Remitted to Governmental
Authorities.
Taxes collected from customers and remitted to governmental
authorities are recognized on a net basis in the accompanying
condensed consolidated statements of operations.
Shipping and Handling Costs.
Our shipping and handling costs billed to customers are included in
revenues and the associated expense is recorded in cost of revenues
for all periods presented.
Deferred Revenue.
Deferred revenue represents contract liabilities. Revenue related
to service contracts is deferred and recognized on a straight-line
basis over the period of the applicable service contract. Costs
associated with these service arrangements are recognized as
incurred.
12
A reconciliation of the changes in the Company’s deferred revenue
balance for the
nine months ended September 26, 2020 and September 28, 2019
is as follows:
|
|
Nine Months Ended
|
|
|
|
September 26, 2020
|
|
|
September 28, 2019
|
|
Balance, beginning of period
|
|
$
|
1,810
|
|
|
$
|
2,225
|
|
Additions to deferral
|
|
|
1,067
|
|
|
|
1,580
|
|
Revenue recognized
|
|
|
(1,516
|
)
|
|
|
(1,892
|
)
|
Deductions from reserves
|
|
|
(3
|
)
|
|
|
(19
|
)
|
Balance, end of period
|
|
|
1,358
|
|
|
|
1,894
|
|
Non-current portion of deferred revenue
|
|
|
286
|
|
|
|
366
|
|
Current portion of deferred revenue
|
|
$
|
1,072
|
|
|
$
|
1,528
|
|
During the nine months ended September 26, 2020 and September 28,
2019, approximately $1.0 million and $1.2 million were recognized
pertaining to amounts deferred as of December 28, 2019 and December
29, 2018, respectively.
Warranty.
The Company currently provides a two-year full warranty on its
products. The associated costs of these warranties are accrued for
upon shipment of the products. The Company’s warranty policy is
applicable to products which are considered defective in their
performance or fail to meet the product specifications. Warranty
costs are reflected in the condensed consolidated statements of
operations as cost of revenues.
A reconciliation of the changes in the Company’s warranty liability
for the nine months ended September 26, 2020 and September 28, 2019
is as follows:
|
|
Nine Months Ended
|
|
|
|
September 26, 2020
|
|
|
September 28, 2019
|
|
Balance, beginning of period
|
|
$
|
536
|
|
|
$
|
860
|
|
Accruals for product warranties
|
|
|
85
|
|
|
|
219
|
|
Cost of warranty claims
|
|
|
(108
|
)
|
|
|
(232
|
)
|
Adjustment to pre-existing warranties
|
|
|
(229
|
)
|
|
|
(334
|
)
|
Balance, end of period
|
|
$
|
284
|
|
|
$
|
513
|
|
Reclassifications.
Certain reclassifications have been made to the prior year
financial statements included in these condensed consolidated
financial statements to conform to the current year presentation.
The reclassifications had no impact on previously reported net loss
or accumulated deficit.
Recent Accounting Standards Not Yet Adopted.
In December 2019, the Financial Accounting Standards Board
(“FASB”) issued Accounting Standards Update (“ASU”) 2019-12,
“Income Taxes (Topic 740): Simplifying the Accounting for Income
Taxes” as part of its initiative to reduce complexity in the
accounting standards. The standard eliminates certain exceptions
related to the approach for intraperiod tax allocation, the
methodology for calculating income taxes in an interim period and
the recognition of deferred tax liabilities for outside basis
differences. The standard also clarifies and simplifies other
aspects of the accounting for income taxes. The standard is
effective for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2020. Early adoption is
permitted. The Company is currently evaluating the impact that this
guidance will have on its financial position and results of
operations, if any.
3. Inventories
The components of the Company’s inventories as of September 26,
2020 and December 28, 2019 are as follows:
|
|
September 26, 2020
|
|
|
December 28, 2019
|
|
Raw materials
|
|
$
|
2,411
|
|
|
$
|
2,043
|
|
Work in process
|
|
|
601
|
|
|
|
1,111
|
|
Finished goods
|
|
|
3,992
|
|
|
|
5,020
|
|
Total inventories
|
|
$
|
7,004
|
|
|